Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib in First-line Metastatic Pancreatic Adenocarcinoma

Trial Profile

Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib in First-line Metastatic Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Dasatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 21 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top